At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INDP Indaptus Therapeutics, Inc.
Closed 10-31 16:00:00 EDT
1.17
-0.07
-5.65%
盘后1.17
+0.000.00%
16:45 EDT
High1.25
Low1.13
Vol48.57K
Open1.25
D1 Closing1.24
Amplitude9.31%
Mkt Cap11.93M
Tradable Cap8.75M
Total Shares10.20M
T/O57.10K
T/O Rate0.65%
Tradable Shares7.48M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.